目前针对高山关节炎的免疫抑制治疗方法
Yoh Arita1,2, Tomohiko Ishibashi2, Yoshikazu Nakaoka2,3
1Department of Cardiology, Japan Community Healthcare Organization Osaka Hospital.
概括
塔卡亚苏动脉炎 (TAK) 治疗正在通过生物修饰性抗风湿药物 (bDMARDs) 发展,如托西利祖马布 (TCZ). 本综述涵盖了它们的使用和管理TAK患者进行手术的指导方针.
科学领域:
- 类风湿病学 类风湿病学
- 心脏病学 心脏病学
- 免疫学 免疫学 免疫学
背景情况:
- 塔卡亚苏动脉炎 (TAK) 是一种罕见的大血管血管炎,导致狭窄,闭塞和动脉瘤.
- 葡萄糖皮质类药物是传统的治疗方法,但生物药物正在出现.
- 托西利祖马布 (TCZ) 和其他bDMARD正在改变TAK的治疗格局.
研究的目的:
- 审查托西利祖马布 (TCZ) 和其他免疫抑制剂在塔卡亚苏动脉炎 (TAK) 的证据.
- 提供关于bDMARDs在TAK管理中的当前状态和指导方针的最新信息.
- 为心脏病专家和外科医生提供有关管理这些新疗法患者的信息.
主要方法:
- 在Takayasu动脉炎 (TAK) 中对bDMARDs的临床研究的文献综述.
- 分析当前的治疗指南和专家建议.
- 讨论TAK患者的侵入性手术和手术的影响.
主要成果:
- 一些bDMARDs,包括TCZ,在治疗TAK方面表现有前途.
- 在TAK中使用bDMARD正在增加.
- 雅努斯激酶抑制剂也可能提供治疗效益.
结论:
- bDMARDs代表了高山动脉炎 (TAK) 治疗的重大进展.
- 准则正在不断发展,以纳入这些新疗法.
- 对于需要进行侵入性干预的bDMARDs患者,需要仔细考虑.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
168
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
168
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
141
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
141
Drugs for Treatment of Ulcerative Colitis in IBD
145
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
145
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
121
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
121
Tumor Immunotherapy
529
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
529
Inflammatory Bowel Disease IV: Pharmacological Management
128
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
128


